Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Livmoniplimab plus Budigalimab in previously ICI-treated hepatocellular carcinoma
2022-502948-13-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, randomised trial of livmoniplimab and budigalimab in hepatocellular carcinoma (HCC) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Best overall response (BOR) of confirmed complete or partial response. Planned start Nov 2023; status: authorised.
02
Drugs
livmoniplimabbudigalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2022-502948-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502948-13-00.